Lupus Activity Index: Assesses disease activity in SLE using clinical and lab parameters.
/3
/3
Enter Parameters
Enter arthritis and renal scores (0-3) and select any additional parameters to calculate the Lupus Activity Index.
Guidelines & Evidence
Verified
Last Review: 2026-07-17
When to Use
When to Use
Global assessment of lupus disease activity in clinical care and research
Serial monitoring of overall SLE activity with a single composite score
Evaluating treatment response in longitudinal cohorts
Complementing organ-specific indices like SLEDAI and BILAG
Rapid clinical assessment in busy practice settings
Patient Population
Adults with confirmed SLE by ACR 1997 or SLICC 2012 criteria. The Lupus Activity Index (LAI) was developed at Johns Hopkins and has been validated in both academic and community rheumatology settings.
Contraindications
Not a substitute for organ-specific assessment in severe organ-threatening disease
Does not capture damage or chronic irreversible changes
May not be sensitive to partial improvement in individual organ systems
How it Works
Components
Physician global assessment (0–3): overall impression of lupus activity
Prednisone dose (0–3): graded by current daily dose
Immunosuppressive therapy (0–3): use of cytotoxic/immunosuppressive agents
Anti-dsDNA (0–3): titre elevation above normal range
Complement levels (0–3): C3 and C4 below lower limit of normal
Proteinuria (0–3): 24-hour urine protein excretion
Extra-renal manifestations (0–3): rash, arthritis, serositis, CNS, haematologic
Scoring Method
Each component is scored from 0 (normal/inactive) to 3 (severely active). The total LAI score is calculated as the sum of all component scores divided by the number of components scored. Using a mean rather than a sum allows the index to remain interpretable even when data for some components are missing. The final score ranges from 0 to 3.
Component Grading (Prednisone)
| Score | Prednisone Dose |
|---|---|
| 0 | None |
| 1 | ≤ 10 mg/day |
| 2 | 11 – 30 mg/day |
| 3 | > 30 mg/day or IV pulse |
Clinical Pearls
Clinical Application
The LAI provides a holistic snapshot of lupus activity that incorporates both clinical and laboratory parameters. Its use of a mean score (rather than a sum) makes it particularly useful in real-world settings where some laboratory data may be unavailable. The inclusion of prednisone dose and immunosuppressive use as activity markers is pragmatic, as treatment intensity reflects the clinician's assessment of disease severity. An increasing LAI over serial visits is a reliable indicator of worsening disease that warrants investigation.
Pitfalls to Avoid
Prednisone dose reflects physician behaviour as much as disease activity; steroid-sparing agents may confound
The LAI is less sensitive than SLEDAI or BILAG for detecting flare in a single organ system
Physician global assessment is subjective and may vary between clinicians
Missing data for individual components is handled by averaging, but this can mask activity in the missing domain
The LAI has been less widely adopted in clinical trials compared to SLEDAI-2K and BILAG
Next Steps
Score Interpretation Guide
| Score Range | Disease Activity | Clinical Action |
|---|---|---|
| 0 – 0.5 | Inactive / quiescent | Maintain current therapy; monitor every 3–6 months |
| 0.6 – 1.2 | Mild | Consider mild adjustments; review medication adherence |
| 1.3 – 2.0 | Moderate | Escalate therapy; consider increased steroids or addition of immunosuppressant |
| 2.1 – 3.0 | Severe | Urgent intervention; hospitalisation may be required |
When to Reassess
Every 1–3 months during active disease
Every 3–6 months in stable disease
Before and after major therapy changes
Immediately on clinical suspicion of flare
The Evidence
Key Evidence
The LAI was validated against expert physician assessment and showed strong concordance
Correlates with SLEDAI and BILAG in cross-sectional studies
Longitudinal LAI scores predict damage accrual and hospitalisation risk
Used in the Hopkins Lupus Cohort, one of the longest-running observational SLE cohorts worldwide
Primary Reference
Validity and reliability of lupus activity measures in the routine clinic setting.
Petri M et al. • Journal of Rheumatology. 1992;19(1):53-9
Combined oral contraceptives in women with systemic lupus erythematosus.
Petri M et al. • New England Journal of Medicine. 2005;353(24):2550-8 (used LAI as activity measure)
Origins & History
Development
The Lupus Activity Index (LAI) was developed by Petri and colleagues at the Johns Hopkins University School of Medicine and published in 1992. It was designed as a practical global activity measure for routine clinical use, balancing comprehensiveness with ease of administration. The LAI has been used extensively in the Hopkins Lupus Cohort, which has followed over 2,500 SLE patients since 1987, contributing substantially to our understanding of lupus outcomes, pregnancy risks, and cardiovascular disease in SLE.
Last Comprehensive Review: 2026-07-17